Regeneron MFN Deal Lowers Prices, Offers Free Gene Therapy
Regeneron MFN deal cuts U.S. drug prices and offers Otarmeni free while securing tariff relief, and may push investors to reprice launch economics.
KEY TAKEAWAYS
- Regeneron agreed to MFN pricing on new medicines, projecting savings in the hundreds of millions.
- Praluent direct-purchase price cut to $225 from $537 through TrumpRx.
- Regeneron pledged $27.0 billion to U.S. R&D and manufacturing by 2029, more than doubling capacity.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Regeneron Pharmaceuticals (REGN) on April 23, 2026, reached a most-favored-nation (MFN) drug pricing agreement with the Trump administration that lowers U.S. prices on select medicines, offers its newly approved gene therapy Otarmeni free to eligible patients, and exchanges pricing concessions for tariff relief.
Pricing Terms, Trade Concessions, and Access
The White House fact sheet said Regeneron agreed to MFN pricing on all new medicines for U.S. patients, including Medicaid, projecting savings in the hundreds of millions of dollars. Regeneron is the 17th company to join the program, which covers roughly 86% of the branded drug market.
As part of the deal, the company will reduce the price of its cholesterol drug Praluent (alirocumab) from $537 to $225 for patients purchasing directly through TrumpRx.gov. The package grants Regeneron 100% tariff immunity on branded drug imports and a three-year reprieve from future pricing mandates tied to increased domestic activity. The Commerce Department will oversee the tariff exemptions.
The agreement also includes the FDA approval of Otarmeni (lunsotogene parvec-cwha) under the Commissioner's National Priority Voucher program, based on Phase I/II CHORD study data (NCT05762536). Otarmeni targets hearing loss caused by mutations in the OTOF gene and is intended for an ultra-rare population of about 50 U.S. births annually. Regeneron will provide the therapy free to eligible patients. Early data showed modest hearing gains, though the rollout has faced criticism from parts of the Deaf community.
U.S. Investment and Strategic Implications
Regeneron committed $27 billion to U.S. research, development, and manufacturing by 2029, aiming to more than double its domestic capacity. These voluntary private agreements align pricing concessions with incentives to repatriate revenue and expand U.S. manufacturing. The Commerce Department will oversee the tariff exemptions.
For investors, the deal trades near-term pricing concessions and broad MFN commitments for tariff relief and explicit incentives to boost domestic capacity, potentially influencing Regeneron’s capital allocation and manufacturing footprint as the plan unfolds.
"Regeneron will reduce the price of its powerful cholesterol medicine, Praluent, from $537 to $225 for patients purchasing directly through TrumpRx," the White House fact sheet said.
